Skip to content
CancerIndex

Publication

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Authors not recorded

Oncotarget2016PMID 27167191PMC5129956stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
27167191
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
KRAS G12C1
PalbociclibMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response—submitted
EID3975

In an in vitro study, SW837 cell line expressing KRAS G12C mutation were associated with sensitivity to palbociclib treatment as compared to cells treated with DMSO control. Sensitivity was determine… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

civic
KRAS G12V1
PalbociclibMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response—submitted
EID3926

In an in vitro study, SKCO1 and SW403 cell lines expressing KRAS G12V mutation were associated with sensitivity to palbociclib treatment as compared to cells treated with DMSO control. Sensitivity wa… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

civic
KRAS G13D1
PalbociclibMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response—submitted
EID3891

In an in vitro study, a Lovo cell line expressing KRAS G13D mutation was associated with sensitivity to palbociclib treatment as compared to cells treated with DMSO control. Sensitivity was determine… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

civic
KRAS Mutation1
Binimetinib + PalbociclibCombinationMalignant Colorectal NeoplasmCURATED_BROADERPredictiveDSupports Sensitivity Response4accepted
EID4869

A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts. The com… (full text at CIViC)

PMID 27167191 · Lee et al., 2016 · Open in CIViC

civic